Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 2 sales; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Climb Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.77M in total
- Insiders trading
- 2
- Net value
- −$1.77M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Climb Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Thomas Stephen Basil | Director | 467,969 | Sep 17, 2026 | 4 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 3,403,429Indirect | Jul 1, 2026 | 5 |
| Ra Capital Management, L.P. | Director, 10% Owner | 3,403,429Indirect | Jul 1, 2026 | 5 |
| Kolchinsky Peter | Director, 10% Owner | 3,403,429Indirect | Jul 1, 2026 | 5 |
| Shah Rajeev M. | Director, 10% Owner | 3,403,429Indirect | Jul 1, 2026 | 5 |
| RA Capital Nexus Fund, L.P. | Director | 3,403,429Indirect | Jul 1, 2026 | 5 |
| RA Capital Nexus Fund II, L.P. | Director | 3,403,429Indirect | Jul 1, 2026 | 5 |
| RA Capital Nexus Fund III, L.P. | Director | 3,403,429Indirect | Jul 1, 2026 | 5 |
| Celebi Breanna Maurine | Director | – | Jul 1, 2026 | 1 |
| Brennan Aoife | President and CEO | 87,731 | Jun 30, 2026 | 2 |
| Williams Douglas E | Director | – | Jun 8, 2026 | 1 |
| Drapkin Kimberlee C | Director | – | Jun 8, 2026 | 1 |
| Cumbo Alexander | Director | – | Jun 8, 2026 | 1 |
| Dunn Judith | Director | – | Jun 8, 2026 | 1 |
| Levin Andrew David | Director | – | Jun 8, 2026 | 1 |
| Driscoll Cindy | Senior Vice President, Finance | – | Jan 8, 2026 | 1 |
| ALTSCHULLER Susan | Chief Financial Officer | – | Jan 8, 2026 | 2 |
| Wilson Perrin Megan | Chief Business Officer | – | Jan 8, 2026 | 1 |
| Pimblett Emily | SVP, Finance & CAO | 18,888 | Jun 20, 2025 | 0 |
| Kaplan Brett | Chief Operating Officer | – | Jan 15, 2025 | 0 |
| Morisset Valerie | EVP, R&D AND CSO | 31,317 | Jul 23, 2024 | 0 |
| Ratcliffe Liam | Director | – | Jun 28, 2024 | 0 |
| Rosenberg Adam Joseph | Director | – | Jun 28, 2024 | 0 |
| Tate Simon | Director | – | Jun 28, 2024 | 0 |
| Azelby Robert | President & CEO | – | Nov 2, 2022 | 0 |
| Bucher James B | EVP and General Counsel | – | Nov 2, 2022 | 0 |
| Lavelle Erin | COO & CFO | – | Nov 2, 2022 | 0 |
| Patterson Leone D | Director | – | Jun 1, 2022 | 0 |
| Blavatnik Len | Other: Affiliate of 10% Owner | 5,009,400 | Aug 16, 2021 | 0 |
| Access Industries Holdings LLC | Other: Affiliate of 10% Owner | 5,009,400 | Aug 16, 2021 | 0 |
| Access Industries Management, LLC | Other: Affiliate of 10% Owner | 5,009,400 | Aug 16, 2021 | 0 |
| AI Eti LLC | 10% Owner | 5,009,400 | Aug 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:15 PM ET | Sep 15 | 2 days | Thomas Stephen BasilDirector | SSale | −100.0K | $13.67 | −$1.37M | −17.6%468.0K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Brennan AoifePresident and CEO | SSale | −30.9K | $13.17 | −$407.0K | −26.0%87.7K after | 10b5-1 |
| Feb 27, 2026 (view filing) | Feb 25-26 | 2 days | Thomas Stephen BasilDirector | SSale | −50.0K | $7.00 | −$350.2K | −24.4%154.7K after | 2 lots10b5-1 |
| Feb 17, 2026 (view filing) | Feb 12-13 | 5 days | Thomas Stephen BasilDirector | SSale | −100.0K | $5.29 | −$528.8K | −32.8%204.7K after | 2 lots10b5-1 |
| Jan 7, 2026 (view filing)4:55 PM ET | Jan 5 | 2 days | RA Capital Healthcare Fund LP and 6 othersDirector, 10% Owner | PPurchase | +7.11K | $3.50 | +$24.9K | +0.2%3.40M after | |
| Dec 15, 2025 (view filing)7:55 PM ET | Dec 11-12 | 4 days | RA Capital Healthcare Fund LP and 6 othersDirector, 10% Owner | PPurchase | +314.6K | $2.40 | +$754.7K | +10.2%3.40M after | 2 lots |
| Jul 1, 2025 (view filing) | Jun 30 | 1 day | Brennan AoifePresident and CEO | SSale | −20.6K | $1.22 | −$25.2K | −30.0%48.1K after | 10b5-1 |
| Jun 20, 2025 (view filing) | Jun 20 | Same day | Pimblett EmilySVP, Finance & CAO | SSale | −1.24K | $1.24 | −$1.54K | −6.2%18.9K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 20 | Same day | Pimblett EmilySVP, Finance & CAO | SSale | −1.20K | $1.31 | −$1.57K | −7.3%15.1K after | 10b5-1 |
| Dec 20, 2024 (view filing) | Dec 19 | 1 day | Pimblett EmilyCHIEF ACCOUNTING OFFICER | SSale | −1.24K | $2.02 | −$2.49K | −9.8%11.3K after | 10b5-1 |
| Sep 20, 2024 (view filing) | Sep 20 | Same day | Pimblett EmilyCHIEF ACCOUNTING OFFICER | SSale | −1.19K | $8.18 | −$9.74K | −13.6%7.56K after | 2 lots10b5-1 |
| Jul 23, 2024 (view filing) | Jul 19-22 | 4 days | Morisset ValerieEVP, R&D AND CSO | SSale | −129.2K | $7.65 | −$988.5K | −80.5%31.3K after | 4 lots |
| Jul 19, 2024 (view filing) | Jul 17-18 | 2 days | Morisset ValerieEVP, R&D AND CSO | SSale | −41.8K | $6.93 | −$289.5K | −20.7%160.5K after | 2 lots |
| Jul 17, 2024 (view filing) | Jul 16 | 1 day | Morisset ValerieEVP, R&D AND CSO | SSale | −50.0K | $7.13 | −$356.5K | −19.8%202.3K after | |
| Jul 16, 2024 (view filing) | Jul 12-15 | 4 days | Morisset ValerieEVP, R&D AND CSO | SSale | −92.4K | $7.04 | −$650.6K | −26.8%252.3K after | 2 lots |
| Jul 11, 2024 (view filing) | Jul 9-11 | 2 days | Morisset ValerieEVP, R&D AND CSO | SSale | −105.9K | $6.95 | −$736.5K | −23.5%344.7K after | 3 lots |
| Jul 9, 2024 (view filing) | Jul 5 | 4 days | Morisset ValerieEVP, R&D AND CSO | SSale | −12.3K | $7.06 | −$87.1K | −2.7%450.6K after | |
| Jul 3, 2024 (view filing) | Jul 3 | Same day | Morisset ValerieEVP, R&D AND CSO | SSale | −50.0K | $6.76 | −$338.0K | −9.7%463.0K after | |
| Jul 1, 2024 (view filing)9:29 PM ET | Jun 27 | 4 days | RA Capital Healthcare Fund LP and 6 othersDirector, 10% Owner | PPurchase | +13.0M | $3.84 | +$50.0M | New position2.87M after | 2 lots |
| Jun 21, 2024 (view filing) | Jun 20 | 1 day | Pimblett EmilyCHIEF ACCOUNTING OFFICER | SSale | −1.25K | $7.21 | −$8.98K | −24.9%3.75K after | |
| Aug 16, 2021 (view filing)4:47 PM ET | Aug 12 | 4 days | RA Capital Healthcare Fund LP and 5 othersDirector, 10% Owner | PPurchase | +3.20M | $12.50 | +$40.0M | New position483.7K after | 2 lots |
| Aug 16, 2021 (view filing)4:21 PM ET | Aug 12 | 4 days | Blavatnik Len and 3 othersOther: Affiliate of 10% Owner | PPurchase | +800.0K | $12.50 | +$10.0M | +19.0%5.01M after |